---
title: 'Funding Daily Summary: What Happened on October 9, 2026'
headline: Matchpoint raises $150 million as Forbion raises €2.3 billion
description: TRex Bio priced a $117 million IPO to fund its immune-drug programs.
url: https://thebench.bio/news/funding/2026-10-09
topic: funding
date: '2026-10-09'
covers:
- '2026-10-09'
date_published: '2026-10-09T12:01:57Z'
date_modified: '2026-10-09T12:01:57Z'
sources: 3
publisher: The Bench (thebench.bio)
---

# Funding Daily Summary: What Happened on October 9, 2026

**Matchpoint raises $150 million as Forbion raises €2.3 billion**

TRex Bio priced a $117 million IPO to fund its immune-drug programs.

## Today in brief

Matchpoint secured $150 million to advance its lead program toward proof of concept, while Forbion raised €2.3 billion in new funds. [1] TRex Bio priced an IPO valued at $117 million to support drug development for immunological conditions. [2]

## Matchpoint raises $150 million, Forbion raises €2.3 billion

Matchpoint will use its $150 million Series B to advance its lead program toward proof of concept. [1] The company, which is developing drugs for immune and inflammatory diseases, launched four years ago with a $100 million Series A. [1] [3]

Forbion raised €2.3 billion in new funds, a record capital raise. [1]

## TRex Bio prices $117 million IPO for immune-drug development

TRex Bio priced an IPO valued at $117 million to fund development of drugs for immunological conditions. [2] Its programs aim to treat those conditions by activating Treg cells. Eli Lilly is the company's largest equity holder. [2]

## The day in numbers

- **$150 million**: Matchpoint's Series B to advance its lead program toward proof of concept. [1]
- **€2.3 billion**: Forbion's new funds, described as a record capital raise. [1]
- **$117 million**: Value of TRex Bio's IPO, which will fund its immune-drug programs. [2]

## Sources

1. [Matchpoint’s $150M tops the week’s private rounds: Venture Report](<https://www.biocentury.com/article/661066/matchpoint-s-150m-tops-the-week-s-private-rounds-venture-report?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-10-09
2. [TRex Bio prices $117M IPO to support immune drug work](<https://www.biopharmadive.com/news/trex-bio-ipo-pricing-autoimmune-tregs/832297/>), BioPharma Dive, 2026-10-09
3. [Matchpoint scores $150m for I&I drugs, and other financings](<https://pharmaphorum.com/news/matchpoint-scores-150m-ii-drugs-and-other-financings>), pharmaphorum, 2026-10-08

---

The Bench wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661066/matchpoint-s-150m-tops-the-week-s-private-rounds-venture-report?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.biopharmadive.com/news/trex-bio-ipo-pricing-autoimmune-tregs/832297/>
[3]: <https://pharmaphorum.com/news/matchpoint-scores-150m-ii-drugs-and-other-financings>